Biotech entity
All 1 tracked stories fall under one category: clinical-trial. Of the tracked stories, 1 of 1 also mention AH-008, the most common co-covered peer. The tracked stories average 1 original source each. AnHorn Medicines appears in 1 tracked Biotech story from July 25, 2026.
Last mentioned: Jul 25, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: clinical-trial. Of the tracked stories, 1 of 1 also mention AH-008, the most common co-covered peer. The tracked stories average 1 original source each. AnHorn Medicines appears in 1 tracked Biotech story from July 25, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 15 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering AnHorn Medicines. Shared-story counts are live from our verified record — not editorial picks.
AnHorn Medicines’ neuroprotective candidate AH-008 cleared FDA IND and received Taiwan CDE Index Case status, advancing into human trials for chemotherapy-induced peripheral neuropathy, a condition with zero approved preventive therapies.
Source: prnewswire.com
AnHorn Medicines is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
